A Single-Center, Randomized, Placebo-Controlled, 3 Treatment Period Crossover Study to Assess the Effect of Padsevonil on Cardiac Repolarization (QTc Interval) (Using Moxifloxacin as a Positive Control) in Healthy Study Participants
Latest Information Update: 21 Jun 2021
At a glance
- Drugs Padsevonil (Primary) ; Moxifloxacin
- Indications Epilepsy
- Focus Pharmacodynamics
- Sponsors UCB Biopharma
Most Recent Events
- 09 Jun 2020 Status changed from suspended to discontinued.
- 20 May 2020 Planned End Date changed from 1 Apr 2020 to 1 May 2020.
- 20 May 2020 Planned primary completion date changed from 1 Apr 2020 to 1 May 2020.